Prelude Therapeutics (PRLD) Projected to Post Earnings on Wednesday

Prelude Therapeutics (NASDAQ:PRLD) will likely be releasing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Friday, November 14, 2025 at 11:30 AM ET.

Prelude Therapeutics (NASDAQ:PRLD) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.04. On average, analysts expect Prelude Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Prelude Therapeutics Stock Up 150.3%

Prelude Therapeutics stock opened at $3.98 on Tuesday. The company’s 50-day moving average price is $1.37 and its 200-day moving average price is $1.06. The company has a market cap of $225.27 million, a PE ratio of -2.43 and a beta of 1.37. Prelude Therapeutics has a twelve month low of $0.61 and a twelve month high of $4.22.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Wall Street Zen raised Prelude Therapeutics to a “hold” rating in a research note on Saturday, October 18th. JMP Securities cut their target price on Prelude Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Monday, August 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Prelude Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Prelude Therapeutics in a research note on Tuesday, September 23rd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $4.00.

Hedge Funds Weigh In On Prelude Therapeutics

Hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC lifted its position in shares of Prelude Therapeutics by 170.7% during the first quarter. AQR Capital Management LLC now owns 33,823 shares of the company’s stock worth $26,000 after purchasing an additional 21,330 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Prelude Therapeutics by 9.1% during the 1st quarter. Acadian Asset Management LLC now owns 529,327 shares of the company’s stock valued at $405,000 after buying an additional 43,946 shares in the last quarter. XTX Topco Ltd lifted its holdings in Prelude Therapeutics by 72.4% during the 2nd quarter. XTX Topco Ltd now owns 42,573 shares of the company’s stock valued at $34,000 after buying an additional 17,873 shares in the last quarter. Marshall Wace LLP purchased a new stake in Prelude Therapeutics in the 2nd quarter valued at about $34,000. Finally, Jane Street Group LLC bought a new position in Prelude Therapeutics in the 2nd quarter worth about $74,000. Institutional investors own 79.72% of the company’s stock.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.